These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 6685916)

  • 21. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera.
    van Genderen PJ; Michiels JJ
    Semin Thromb Hemost; 1997; 23(4):357-63. PubMed ID: 9263352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Polycythaemia vera--diagnosis and therapy].
    Lechner K; Geissler K; Gisslinger H
    Wien Klin Wochenschr; 1999 Aug; 111(15):582-9. PubMed ID: 10483672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.
    Passamonti F; Rumi E; Pungolino E; Malabarba L; Bertazzoni P; Valentini M; Orlandi E; Arcaini L; Brusamolino E; Pascutto C; Cazzola M; Morra E; Lazzarino M
    Am J Med; 2004 Nov; 117(10):755-61. PubMed ID: 15541325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin.
    van Genderen PJ; Michiels JJ; van Strik R; Lindemans J; van Vliet HH
    Thromb Haemost; 1995 Feb; 73(2):210-4. PubMed ID: 7792731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The myeloproliferative disorders. An historical appraisal and personal experiences.
    Michiels JJ
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():1-14. PubMed ID: 8951768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.
    Elliott MA; Tefferi A
    Curr Hematol Rep; 2004 Sep; 3(5):344-51. PubMed ID: 15341701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polycythemia vera and mesenteric arterial thrombosis. A disease association resulting from decreased platelet sensitivity to aspirin.
    Myers TJ; Steinberg WM; Rickles FR
    Arch Intern Med; 1979 Jun; 139(6):695-8. PubMed ID: 443976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Essential thrombocythemia: antiaggregants].
    Cortelazzo S; Barbui T
    Haematologica; 1991 Jun; 76 Suppl 3():371-3. PubMed ID: 1752535
    [No Abstract]   [Full Text] [Related]  

  • 29. Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia.
    Randi ML; Rossi C; Fabris F; Menapace L; Girolami A
    Clin Appl Thromb Hemost; 1999 Apr; 5(2):131-5. PubMed ID: 10725994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [What vascular events suggest a myeloproliferative disorder?].
    Hachulla E; Rose C; Trillot N; Caulier-Leleu MT; Pasturel-Michon U
    J Mal Vasc; 2000 Dec; 25(5):382-387. PubMed ID: 11148402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expertise-based management in essential thrombocythemia and polycythemia vera.
    Finazzi G; Barbui T
    Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia.
    Cucuianu A; Stoia M; Farcaş A; Dima D; Zdrenghea M; Paţiu M; Olinic D; Petrov L
    Rom J Intern Med; 2006; 44(4):397-406. PubMed ID: 18386616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives.
    Landolfi R; Patrono C
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():83-6. PubMed ID: 8951777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Titrated initiation of acetylsalicylic acid-dipyridamole therapy reduces adverse effects and improves tolerance in patients with stroke.
    Douen AG; Medic S; Sabih M; Pageau N; Shuaib A
    J Stroke Cerebrovasc Dis; 2008; 17(6):356-9. PubMed ID: 18984426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
    Landolfi R; Di Gennaro L; Falanga A
    Leukemia; 2008 Nov; 22(11):2020-8. PubMed ID: 18800144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.
    Jurgens DJ; Moreno-Aspitia A; Tefferi A
    Haematologica; 2004 Nov; 89(11):1394-5. PubMed ID: 15531464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiplatelet therapy in the management of myeloproliferative neoplasms.
    Alvarez-Larrán A; Besses C
    Curr Hematol Malig Rep; 2014 Dec; 9(4):319-23. PubMed ID: 25120015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
    Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
    Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Complications of antithrombotic prophylaxis with acetylsalicylic acid (ASS) in polycythemia (author's transl)].
    Ranft K; Brands W
    Med Klin; 1978 Jun; 73(22):839-42. PubMed ID: 307109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.